Latest News

Cataract original papers on intracameral antibiotics and IOL power, a guideline-based case symposium, and ocular surface sessions headline AAO 2026.

Ashish Sharma, MD, on what real-world data show about switching and long-term outcomes with retinal biosimilars.

Could one surgery replace years of GA injections? Phase 2 ArMaDa data suggest gene therapy OCU410 slows lesion growth.

• The American Academy of Ophthalmology 2026 annual meeting is set for October 9-12 in New Orleans.

Kareem Moussa, MD, discusses how four local corticosteroid injections compare on effectiveness and IOP, and what that means for choosing among them.

4DMT's 4D-150 gene therapy enters phase 3 4SIGHT trial in DME; 2-year SPECTRA data show +10.8-letter BCVA gain in 9 patients.

Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.

Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.

Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.

Three studies use OCT and OCTA to track AMD treatment response, flag diabetic retinopathy before oedema and confirm ocular toxoplasmosis.

Japan's filing covers IRDs broadly, supported by RESTORE and open-label Stargardt data.

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

Sharon Fekrat, MD, FACS, FASRS, discusses how retinal imaging fits into the diagnostic picture for CVI, TBI, and neurodegenerative disease.